Device-associated healthcare-acquired infections (DA-HAI) pose a threat to patient safety in the intensive care unit (ICU)” Empaire et al (2017).
BACKGROUND: Device-associated healthcare-acquired infections (DA-HAI) pose a threat to patient safety in the intensive care unit (ICU).
ReTweet if useful… CLABSI rates and bacterial resistance in intensive care units of Venezuela https://ctt.ec/ObWe3+ @ivteam #ivteam
METHODS: A DA-HAI surveillance study was conducted by the International Nosocomial Infection Control Consortium (INICC) in two adult medical/surgical ICUs at two hospitals in Caracas, Venezuela, in different periods from March 2008 to April 2015, using the US Centers for Disease Control and Prevention’s National Healthcare Safety Network (CDC/NHSN) definitions and criteria, and INICC methods.
RESULTS: We followed 1041 ICU patients for 4632 bed days. Central line-associated bloodstream infection (CLABSI) rate was 5.1 per 1000 central line days, ventilator-associated pneumonia (VAP) rate was 7.2 per 1000 mechanical ventilator days, and catheter-associated urinary tract infection (CAUTI) rate was 3.9 per 1000 urinary catheter days, all similar to or lower than INICC rates (4.9 ; 16.5 ; 5.3 ), and higher than CDC/NHSN rates (0.8 ; 1.1 ; and 1.3 ). Device utilization ratios were higher than INICC and CDC/NHSN rates, except for urinary catheter, which was similar to INICC. Extra length of stay was 8 days for patients with CLABSI, 9.6 for VAP and 5.7 days for CAUTI. Additional crude mortality was 3.0% for CLABSI, 4.4% for VAP, and 16.9% for CAUTI.
CONCLUSIONS: DA-HAI rates in our ICUs are higher than CDC/NSHN’s and similar to or lower than INICC international rates.
Empaire, G.D., Guzman Siritt, M.E., Rosenthal, V.D., Pérez, F., Ruiz, Y., Díaz, C., Di Silvestre, G., Salinas, E. and Orozco, N. (2017) Multicenter prospective study on device-associated infection rates and bacterial resistance in intensive care units of Venezuela: International Nosocomial Infection Control Consortium (INICC) findings. International Health. 9(1), p.44-49.
Thank you to our partners for supporting IVTEAM